

# Richard E Kanner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916737/publications.pdf>

Version: 2024-02-01

46  
papers

2,569  
citations

304368

22  
h-index

233125

45  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Impact of Depressive Symptoms and FEV <sub>1</sub> % on Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 171-178.	1.5	7
2	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2022, 9, 111-121.	0.5	6
3	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. <i>Science of the Total Environment</i> , 2022, 829, 154694.	3.9	9
4	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 987-997.	2.5	38
5	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 326-335.	0.5	0
6	Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1822-1831.	1.5	5
7	The influence of social support on COPD outcomes mediated by depression. <i>PLoS ONE</i> , 2021, 16, e0245478.	1.1	8
8	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. <i>Scientific Reports</i> , 2021, 11, 4916.	1.6	12
9	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>International Journal of COPD</i> , 2021, Volume 16, 1477-1496.	0.9	8
10	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1241-1254.	5.2	80
11	Ratio of FEV <sub>1</sub> /Slow Vital Capacity of 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. <i>Chest</i> , 2021, 160, 94-103.	0.4	8
12	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 536-545.	2.5	17
13	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. <i>JAMA Internal Medicine</i> , 2020, 180, 106.	2.6	49
14	&lt;p&gt;Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1887-1898.	0.9	2
15	&lt;p&gt;Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2467-2476.	0.9	11
16	Serum IgG Levels and Risk of COPD Hospitalization. <i>Chest</i> , 2020, 158, 1420-1430.	0.4	22
17	Clinical Phenotypes of Atopy and Asthma in COPD. <i>Chest</i> , 2020, 158, 2333-2345.	0.4	19
18	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2020, 7, 370-381.	0.5	5

#	ARTICLE	IF	CITATIONS
19	A Risk Prediction Model for Mortality Among Smokers in the COPD Gene <sup>®</sup> Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 346-361.	0.5	9
20	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. <i>Scientific Reports</i> , 2019, 9, 11367.	1.6	20
21	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). <i>Respiratory Research</i> , 2019, 20, 153.	1.4	25
22	&lt;p&gt;Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 2927-2938.	0.9	16
23	Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers. <i>Korean Journal of Radiology</i> , 2019, 20, 1236.	1.5	13
24	Human airway branch variation and chronic obstructive pulmonary disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E974-E981.	3.3	80
25	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. <i>Annals of the American Thoracic Society</i> , 2018, 15, 808-816.	1.5	32
26	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. <i>Respiratory Research</i> , 2018, 19, 223.	1.4	12
27	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Respiratory Research</i> , 2018, 19, 178.	1.4	20
28	Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1411-1419.	1.5	27
29	Genome-wide association study of lung function and clinical implication in heavy smokers. <i>BMC Medical Genetics</i> , 2018, 19, 134.	2.1	28
30	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. <i>Annals of the American Thoracic Society</i> , 2018, 15, 710-717.	1.5	32
31	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. <i>Respiratory Medicine</i> , 2018, 140, 87-93.	1.3	18
32	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 636-642.	1.5	30
33	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000252.	1.2	30
34	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 956-967.	5.2	211
35	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 619-626.	5.2	219
36	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 464-472.	2.5	59

#	ARTICLE	IF	CITATIONS
37	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	2.5	101
38	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	1.1	20
39	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. New England Journal of Medicine, 2016, 374, 1811-1821.	13.9	526
40	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806.	2.5	180
41	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	1.5	88
42	Effect of Naturally Occurring Ozone Air Pollution Episodes on Pulmonary Oxidative Stress and Inflammation. International Journal of Environmental Research and Public Health, 2015, 12, 5061-5075.	1.2	28
43	Characteristics of Alpha-1 Antitrypsin Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2015, 12, 1796-1804.	1.5	15
44	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1. Thorax, 2014, 69, 492-495.	2.7	277
45	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	2.7	114
46	Selection of Spirometric Measurements in a Clinical Trial, the Lung Health Study. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 675-681.	2.5	33